| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Viracta Therapeutics, Inc. (VIRX) has 0 insiders with recent SEC Form 4 filings, including 14 buys and 2 sells. VIRX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2021 | Royston Ivor | CEO &President | Sale+OE | 27,747 | $4.81 | $133,495.16 | -2.3% | |
| Nov 15, 2021 | Royston Ivor | CEO &President | Buy | 8,000 | $5.56 | $44,480.00 | +1.5% | |
| May 29, 2020 | Gullotta Tina | VP, Finance | Buy | 6,000 | $0.33 | $1,989.00 | +41.4% | |
| Nov 29, 2019 | Quinn William P. | See Remarks | Buy | 12,000 | $0.51 | $6,069.60 | +5.1% | |
| Jul 15, 2019 | Aisling Capital Iv, LP | 10% Owner | Buy | 2,500,000 | $0.60 | $1,500,000.00 | +32.9% | |
| Dec 10, 2018 | Quinn William P. | CFO,Sr.v.p. Finance, Corp.dev. | Buy | 40,000 | $0.47 | $18,800.00 | +333.3% | |
| Nov 6, 2017 | Mpm Oncology Impact Management GP LLC | 10% Owner | Buy | 81,500 | $2.77 | $226,001.00 | +0.8% | |
| Oct 27, 2017 | Misfeldt Dayton | Director | Buy | 400,000 | $2.00 | $800,000.00 | +32.6% | |
| Dec 9, 2016 | Parker Geoffrey M.47 | Director | Buy | 3,740 | $3.87 | $14,476.96 | +2.9% | |
| May 26, 2016 | Parker Geoffrey M.47 | Director | Buy | 9,500 | $0.47 | $4,454.55 | +18.1% |